PHIRE

Health programs crave for diagnostic imaging and eradication of chemoresistant neoplastic lesions smaller than 1 mm of size. PHIRE aims at bringing closer to market a novel high-resolution theranostic medical device effective in the clinical applications for lesions <1 mm, ready for application in human bladder cancer and effective both in male and female patients. The Consortium is composed by hospital, academia and industrial researches located in Italy (San Raffaele Hospital and University of Bologna), United Kingdom (Ascend Technologies LTD), The Netherlands (Fujifilm Visualsonics) and Belgium (META Group). Funding by the Horizon Europe programme, under GA No. 101113193